Mirxes Hong Kong, a company championing a shift towards preventive medicine, has successfully closed its Series D funding round, raising a substantial $910.0M. The Singapore-headquartered firm, which maintains operational teams across mainland China, Japan, the US, and Hong Kong, extends its reach to over 45 countries globally.
The company's core mission revolves around leveraging continuous scientific innovation to provide high-quality solutions in preventive medicine, believing that the future of healthcare lies in early detection and prevention rather than solely in treatment.














